Who makes GLPG3312 MR?

GLPG3312 MR is developed by Galapagos NV.

Last reviewed 2026-04-19 · How we verify

GLPG3312 MR

Galapagos NV · Phase 1 active Small molecule

At a glance

Generic name	GLPG3312 MR
Sponsor	Galapagos NV
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GLPG3312 MR CI brief — competitive landscape report
GLPG3312 MR updates RSS · CI watch RSS
Galapagos NV portfolio CI